Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KALV
stocks logo

KALV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is 31.14 USD with a low forecast of 27.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is 31.14 USD with a low forecast of 27.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.400
sliders
Low
27.00
Averages
31.14
High
39.00
Current: 16.400
sliders
Low
27.00
Averages
31.14
High
39.00
Citizens JMP
Outperform
maintain
$29 -> $28
2025-11-11
Reason
Citizens JMP
Price Target
$29 -> $28
2025-11-11
maintain
Outperform
Reason
Citizens JMP lowered the firm's price target on KalVista to $28 from $29 and keeps an Outperform rating on the shares. Early demand for Ekterly looks strong, with 937 start forms as of the end of October, covering roughly 8% of the diagnosed U.S. hereditary angioedema population, the analyst tells investors in a research note. The 937 start forms represent about $31M in potential revenue, the firm notes, adding that the early demand is "promising."
BofA
Buy
downgrade
$36 -> $29
2025-10-22
Reason
BofA
Price Target
$36 -> $29
2025-10-22
downgrade
Buy
Reason
BofA lowered the firm's price target on KalVista to $29 from $36 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
Citizens JMP
Jonathan Wolleben
Outperform
maintain
$27 -> $28
2025-09-12
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$27 -> $28
2025-09-12
maintain
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben raised the firm's price target on KalVista to $28 from $27 and keeps an Outperform rating on the shares. Ekterly has seen robust early demand with 460 patient start forms which represents about $31M in potential revenue, but all patients get 4 doses of free drug and realization of that revenue depends on having and treating attacks and payer access, the analyst tells investors in a research note. The firm adds that consensus estimates near-term will be "unreliable" as KalVista is changing its fiscal year reporting.
Citizens JMP
Jonathan Wolleben
Outperform
maintain
$19 -> $27
2025-07-08
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$19 -> $27
2025-07-08
maintain
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben raised the firm's price target on KalVista to $27 from $19 and keeps an Outperform rating on the shares. Ekterly is poised for a strong launch given the unmet need, clinical profile, and desire from patients for an oral on-demand therapy, though KalVista priced the drug higher than current injectables, which range from ~$4K-$11K per dose and ~$11K-$17K per attack, the analyst tells investors in a research note.
BofA
Buy
upgrade
$22 -> $37
2025-07-08
Reason
BofA
Price Target
$22 -> $37
2025-07-08
upgrade
Buy
Reason
BofA raised the firm's price target on KalVista to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary angioedema attacks with a broad label and no restrictions on type of HAE attack or background LTP usage for patients 12 and older. The firm, which says the approval was in-line with its expectations and it is "encouraged by the broad label," remains "bullish" on Ekterly's differentiation as the only oral on-demand treatment on the market, the analyst tells investors.
H.C. Wainwright
Buy
downgrade
$30 -> $27
2025-07-08
Reason
H.C. Wainwright
Price Target
$30 -> $27
2025-07-08
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on KalVista to $27 from $30 and keeps a Buy rating on the shares. The firm says a recurring concern in its talks with key opinion leaders is the challenge facing KalVista of securing insurance coverage for Ekterly. The leaders would lack a strong clinical argument to justify Ekterly as medically superior if coverage were denied, given the absence of head-to-head data showing superiority over existing on-demand options like icatibant, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kalvista Pharmaceuticals Inc (KALV.O) is -4.38, compared to its 5-year average forward P/E of -4.06. For a more detailed relative valuation and DCF analysis to assess Kalvista Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.06
Current PE
-4.38
Overvalued PE
-1.92
Undervalued PE
-6.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.53
Undervalued EV/EBITDA
-1.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
166.52
Current PS
0.00
Overvalued PS
694.63
Undervalued PS
-361.59
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 358.75% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 7382.63% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 358.75% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KALV News & Events

Events Timeline

(ET)
2025-11-10
16:34:47
KalVista announces Q3 EPS of 92 cents, compared to 84 cents in the previous year.
select
2025-10-06 (ET)
2025-10-06
16:01:14
KalVista unveils new findings on Ekterly in Europe
select
2025-09-24 (ET)
2025-09-24
16:04:04
KalVista reveals $110M offering of convertible senior notes
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
12-03Benzinga
Marvell Reports Impressive Q3 Earnings, Alongside American Eagle, Microchip Technology, Box, and Other Major Stocks Rising on Wednesday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining approximately 100 points on Wednesday.

  • Marvell Technology Earnings Report: Marvell Technology, Inc. reported better-than-expected third-quarter earnings, with adjusted earnings of 76 cents per share and revenue of $2.08 billion, leading to a 7.5% increase in its stock price.

  • Notable Stock Gains: Several companies saw significant stock price increases, including Ambitions Enterprise Management Co. (up 32%), MapLight Therapeutics, Inc. (up 23%), and Aeva Technologies, Inc. (up 19.9%).

  • Other Companies' Performance: American Eagle Outfitters, Inc. and Microchip Technology Incorporated also reported strong earnings, contributing to their respective stock price increases of 13.3% and 9.5%.

[object Object]
Preview
9.0
12-03Benzinga
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data

  • Pharvaris Phase 3 Trial Results: Pharvaris N.V. announced positive topline data from the RAPIDe-3 Phase 3 trial of deucrictibant, showing significant improvements in the on-demand treatment of hereditary angioedema (HAE) attacks, including faster symptom relief compared to placebo.

  • Market Authorization Plans: The data from the trial will support marketing authorization applications planned for submission starting in the first half of 2026, as the company aims to bring deucrictibant to market.

  • Competitive Landscape: The approval of competing treatments for HAE, such as Ionis Pharmaceuticals' Dawnzera and KalVista Pharmaceuticals' Ekterly, highlights the growing market for HAE therapies, with both products demonstrating significant efficacy in reducing attack rates.

  • Stock Performance: Following the announcement, Pharvaris shares rose by 12.32%, reflecting positive investor sentiment regarding the trial results and the potential market impact of deucrictibant.

[object Object]
Preview
8.0
11-27NASDAQ.COM
Significant Options Trading on Wednesday: WMT, KALV, MTDR

  • KalVista Pharmaceuticals Options Activity: KalVista Pharmaceuticals Inc (KALV) has seen a significant options volume of 10,031 contracts today, equating to about 1.0 million underlying shares, which is 74.6% of its average daily trading volume over the past month.

  • High Volume Put Option for KALV: The $12.50 strike put option expiring on December 19, 2025, has particularly high activity, with 10,013 contracts traded, representing approximately 1.0 million underlying shares.

  • Matador Resources Options Activity: Matador Resources Co (MTDR) has recorded an options volume of 13,784 contracts today, representing around 1.4 million underlying shares, or 72.9% of its average daily trading volume over the past month.

  • High Volume Put Option for MTDR: The $67.50 strike put option expiring on January 16, 2026, has seen notable trading with 5,460 contracts, which corresponds to approximately 546,000 underlying shares.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kalvista Pharmaceuticals Inc (KALV) stock price today?

The current price of KALV is 16.4 USD — it has increased 11.87 % in the last trading day.

arrow icon

What is Kalvista Pharmaceuticals Inc (KALV)'s business?

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.

arrow icon

What is the price predicton of KALV Stock?

Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is 31.14 USD with a low forecast of 27.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kalvista Pharmaceuticals Inc (KALV)'s revenue for the last quarter?

Kalvista Pharmaceuticals Inc revenue for the last quarter amounts to 13.69M USD, decreased % YoY.

arrow icon

What is Kalvista Pharmaceuticals Inc (KALV)'s earnings per share (EPS) for the last quarter?

Kalvista Pharmaceuticals Inc. EPS for the last quarter amounts to -0.92 USD, increased 9.52 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kalvista Pharmaceuticals Inc (KALV)'s fundamentals?

The market is revising Upward the revenue expectations for KalVista Pharmaceuticals, Inc. (KALV) for FY2025, with the revenue forecasts being adjusted by 100.32% over the past three months. During the same period, the stock price has changed by 3.67%.
arrow icon

How many employees does Kalvista Pharmaceuticals Inc (KALV). have?

Kalvista Pharmaceuticals Inc (KALV) has 270 emplpoyees as of December 05 2025.

arrow icon

What is Kalvista Pharmaceuticals Inc (KALV) market cap?

Today KALV has the market capitalization of 828.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free